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Abstract #1182615

Introduction: Hyponatremia is a known complication after
transsphenoidal pituitary surgery (TSS), most commonly caused
by syndrome of inappropriate antidiuretic hormone secretion
(SIADH) and rarely caused by cerebral salt-wasting (CSW).
Differentiating between these two etiologies remains a clinical
challenge but is important as they have opposing treatments.
We present a case of a man who underwent TSS for nonfunctional pituitary macroadenoma and subsequently developed
CSW.
Case Description: A 67 year-old man with no signiﬁcant past
medical history presented to the emergency department with
sudden-onset headaches. CT head showed a 3.3 cm sellar mass.
Dedicated MRI pituitary imaging showed a 3.6 x 2.3 x 2.2 cm
sellar mass with superior displacement of the optic chiasm,
invasion into the cavernous sinus, and features suggesting pituitary apoplexy. Preoperative biochemical evaluation showed
no pituitary hormonal abnormalities. The patient was given
dexamethasone to decrease cerebral edema and underwent
emergent transsphenoidal pituitary tumor resection. Final pathology showed pituitary adenoma with extensive necrosis and
negative staining for ACTH, GH, TSH, and prolactin. Postoperative course was complicated by hyponatremia, central
adrenal insufﬁciency requiring hydrocortisone, and bacterial
meningitis requiring IV antibiotics. Serum sodium was 129
mEq/L with corresponding serum osmolality 280 mOsm/kg,
urine sodium 117 mEq/L, and urine osmolarity 755 mOsm/kg,
suggesting SIADH or CSW. The patient was treated with 1 liter
ﬂuid restriction and sodium chloride tablets up to 4 grams
three times daily for presumed SIADH. On re-evaluation for
refractory hyponatremia, he had orthostatic hypotension with
adequate urine output which distinguishes CSW from SIADH.
The patient was taken off ﬂuid restriction and received volume
repletion with isotonic saline. Serum sodium levels improved
with appropriate rate of correction. The patient was discharged
home on physiologic dose hydrocortisone and sodium chloride
tablets 1 gram three times daily to maintain adequate serum
sodium levels.
Discussion: This rare case of a patient with CSW after TSS,
complicated by postoperative central adrenal insufﬁciency and
bacterial meningitis, highlights the difﬁculty in diagnosing the
etiology of hyponatremia and the importance of distinguishing
CSW from the more common SIADH as the treatments are
opposing. When evaluating hyponatremia, we should assess
serum osmolality, urine sodium, and urine osmolality. SIADH
and CSW can both cause inappropriately concentrated urine, so
we must assess volume status to distinguish between the two.
SIADH causes euvolemic hyponatremia, whereas CSW causes
hypovolemic hyponatremia with positive orthostatics, hypotension, poor skin turgor, decreased central venous pressure, or
elevated hematocrit. SIADH is treated with ﬂuid restriction,
whereas CWS is treated with volume repletion with either
isotonic saline for mild to moderate cases or 3% hypertonic saline for severe cases. Outpatient management with sodium
chloride tablets may be necessary as CSW may not resolve until
weeks to months from onset.

Introduction: Coronavirus disease 2019 (COVID-19) infection has
led to multiple endocrinopathies. We present a case of panhypopituitarism induced by COVID -19 infection.
Case Description: 76 yo male with history of type 2 diabetes, hypertension, and 1.5 cm stable, nonfunctioning, pituitary macroadenoma diagnosed in 2017 had multiple admissions for altered
mental status and hyponatremia following COVID-19 infection in
April 2020. Workup revealed low free T4 0.60 ng/dL (0.8-1.8), low
random cortisol 1.8 mcg/dL(2.9-19.4), high prolactin 33.5 ng/mL (218), low total testosterone < 10 ng/dl (175-781), SHBG 32.7 nmol/L
(13.3-89.5), and low gonadotropins.
While hospitalized, he was diagnosed with pan-hypopituitarism
and started on glucocorticoids and levothyroxine. Repeat MRI pituitary done after discharge, documented stability of the macroadenoma without hemorrhage.
To date, the patient remains on glucocorticoid replacement and
thyroid hormone replacement in stable state.
Discussion: Hypopituitarism from any etiology has an incidence of
4.2 per 100,000. Hormone replacement therapy remains the
mainstay of treatment. This case represents a patient who had
unexplained recurrent hyponatremia after COVID-19 infection and
later diagnosed with pan-hypopituitarism.
Given the continued pandemic, more endocrinopathies related to
the COVID-19 infection have been reported. We have data for other
viral infections, such as SARS and Dengue, documenting pituitary
dysfunction. Review of literature documents SARS infection leading to
post infectious hypophysitis with resulting secondary hypocortisolism
and hypothyroidism. The cause was thought to be virus binding to
pituitary angiotensin-converting enzyme 2 (ACE2) receptors. There is
also data supporting COVID-19 infection leading to pituitary apoplexy
and hypophysitis, though the number of cases reported is limited.
The pathophysiology is thought to be the COVID 19 virus binding
to pituitary ACE2 receptors for which it has a 10-20-fold higher
afﬁnity. Furthermore, the hypothalamus also expresses ACE2 receptors making it a target for the virus. The binding leads to cellular
destruction and autoimmune collateral damage. Hypothalamic pituitary dysfunction could be due to direct effect of virus. The virus
can also lead to reversible hypophysitis.
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